Enhancing immunity to influenza in elderly individuals through reversal of immune senescence mediated by herpes virus infection | Not Recruiting
Enhancing immunity to influenza in elderly individuals through reversal of immune senescence mediated by herpes virus infection
ASPIRE
Trial Source

There is no location for this trial

Location data is sourced from multiple external providers and UKCTG is not responsible for and cannot guarantee the accuracy of data.

Health Conditions
  • Topic: Primary Care Research Network for England, Inflammatory and Immune System
  • Subtopic: Not Assigned, Inflammatory and Immune System (all Subtopics)
  • Disease: Immunology and inflammation, All Diseases
Primary Contact Details
Not Recruiting
Recruitment Status
ISRCTN24967173
Primary Trial ID Number
Summary
Background and study aims? Flu is a major health concern and although flu vaccination is given every year to people over the age of 65 years, a lot of people make a poor immune response to the vaccine. It is now clear that one reason why older people can develop problems with their immune system (body’s protectio¬n mechanism to defend against microbes, bacteria, viruses) is that they carry chronic viral infections such as cytomegalovirus (CMV). The immune system has to work very hard to control these infections and this ‘diverts’ them away from new infections such as flu. We propose to use drugs that fight viruses known as anti-viral drugs (often used to treat diseases such as cold sores) to lessen the strength of CMV and therefore allow the immune system to recover from fighting the virus. We anticipate that the immune system will then make a stronger response to flu vaccination. In the first part of the study we will find the dose that works best and see how long it needs to be taken for. In the second part we will use this dose in a larger group of patients receiving their flu vaccine. We will therefore test if this treatment works well. If proven, this treatment could be valuable in a wide range of clinical conditions and could help to promote healthy ageing. Who can participate? To take part you need to be aged over 65 and a healthy volunteer. What does the study involve? Part One: If you take part, you will be asked to give a small sample of blood taken for testing in the lab to check if you are eligible to take part in this study. If you are eligible then you will be contacted by the ASPIRE team and invited back to another clinic at your surgery. A member of the team will discuss the study with you again and check that there have been no changes to your health or any medication you are currently taking. You will then be asked to sign another consent form before donating a blood and urine sample for baseline analysis. A computer will decide at random (like rolling a dice) what dose of the treatment drug you will be prescribed. Your GP will prescribe the medication the computer chooses for you using a standard prescription that can be collected from one of our designated pharmacies, and this medication needs to be taken every day for the prescribed length of time (three or six months). Over the course of the next six months, your GP or practice nurse will see you at monthly intervals to complete a questionnaire, collect blood and urine samples and prescribe the following month’s medication. In addition to this, you will be seen at two follow-up clinics; nine months after entering the study and again after 12 months. Part Two: If you take part, you will be asked to give a small sample of blood taken for testing in the lab to check if you are eligible to take part in this study. If you are eligible then you will be contacted by the ASPIRE team and invited back to another clinic at your surgery. A member of the team will discuss the study with you again and check that there have been no changes to your health or any medication you are currently taking. You will then be asked to sign another consent form before donating a blood sample for baseline analysis. A computer will decide at random which type of treatment you will have. Half of the people taking part will be prescribed the medication and the other half will be prescribed a placebo capsule (a placebo tablet looks exactly the same as the active medication but contains no active drug). Your GP will prescribe the medication the computer chooses for you using a standard prescription that can be collected from one of our designated pharmacies, and this medication needs to be taken every day for the prescribed length of time (three months). After two months an appointment will be made at your surgery to have a seasonal flu vaccination. At this point a further blood sample will be taken and questionnaire completed. Over the course of the next four months, your GP or practice nurse will see you for follow-up clinics at regular intervals (14, 21, 28 days and four months) to complete a questionnaire and collect a blood sample. What are the possible benefits and risks of participating? Depending on the group you end up in it is possible that your immune system will have improved by taking the treatment and therefore the flu vaccine you receive may be more effective. However it is possible that you will not benefit directly from taking part in this study if you are in the placebo group. Information learnt from studies using your and other participants’ samples may help to improve and develop new treatments for patients suffering from different diseases/conditions. All drugs have side-effects, and no drug is without risk. However, the drugs used in this study are all standard and your GP will be able to adjust them should you suffer any side effects. Should you be concerned about any symptoms that you are experiencing, which you believe could be side effects resulting from the study medication which your GP has prescribed, you are advised to come back and see the GP. Where is the study run from? ASPIRE is being coordinated by the Primary Care Clinical Research and Trials Unit (PCCRTU, fully accredited by the National Institute for Health Research as a trials unit) at the University of Birmingham. We will initially be working with General Practices within the Midland Research Practices Consortium (MidReC). When is the study starting and how long is it expected to run for? The study be open to participants, from approximately November 2011 and will run for approximately three years. Who is funding the study? This study is funded by the Medical Research Council. Who is the main contact? Dr Odette Chagoury (Trial Manager) o.l.chagoury@bham.ac.uk
Research Details
  • ASPIRE - A Study Promoting the Influenza Response in the Elderly. We intend to treat immunocompetent elderly individuals with the anti-viral drug valaciclovir in order to reduce the level of endogenous cytomegalovirus (CMV) replication. This is expected to subsequently reduce the magnitude of the CMV-specific immune response and therefore enhance immunity to other infections. This will be investigated by monitoring the immune response to influenza vaccination.
Phase
Phase II
Study Design
ASPIRE is a two-part study: Part One: Dose-finding study. Part Two: Phase II randomised controlled trial
Study Type
Interventional
Intervention

Valaciclovir Hydrocloride, Part One: 50 eligible patients will be randomised into five treatment arms and the optimal treatment dose and duration of valaciclovir to suppress CMV levels by 85% determined over six months of treatment and six months follow-up. Placebo, Part Two: Half of the eligible patients (110) will be randomly allocated to placebo treatment. The duration and timing of treatment will be designed to match the active treatment arm. Both arms will receive a seasonal influenza vaccine after treatment and the immune response they mount quantified. Part Two: Half of the eligible patients (110) will be randomly allocated to valaciclovir treatment. The dose, duration and timing of treatment will be determined from Part One. Both arms will receive a seasonal influenza vaccine after treatment and the immune r; Follow Up Length: 12 month(s); Study Entry : Registration and One or More Randomisations

Intervention Type
Drug
Primary Outcome Measures
  • The magnitude of the CMV-specific CD8+ T cell immune response.; Timepoint(s): Part One:
  • Screening
  • Baseline
  • Months 1,2,3,4,5,6,9,12
Secondary Outcome Measures
  • 1. Quality of Life; Timepoint(s): Part One: Baseline, Months 1,2,3,4,5,6,9,12
  • 2. The CMV viral load in urine.; Timepoint(s): Part One: Baseline, Months 1,2,3,4,5,6,9,12
  • 3. The improvement in proportion of individuals making an adequate response to seasonal flu; Timepoint(s): Part Two: 14, 21, 28, 120 days post-vaccination
  • 4. The magnitude of the CMV-specific CD4+ T cell immune response.; Timepoint(s): Part One: Screening, Baseline, Months 1,2,3,4,5,6,9,12
  • 5. The magnitude of the influenza-specific CD4+ T cell immune response.; Timepoint(s): Part Two: Baseline, Months 1 & 2, Vaccination - 14, 21, 28, 120 days post-vaccination
  • 6. The magnitude of the influenza-specific CD8+ T cell immune response.; Timepoint(s): Part Two: Baseline, Months 1 & 2, Vaccination - 14, 21, 28, 120 days post-vaccination
  • 7. The titre of the CMV-specific antibody response.; Timepoint(s): Part One: Screening, Baseline, Months 1,2,3,4,5,6,9,12
  • 8. The titre of the H1, H3 and influenza B antibodies.; Timepoint(s): Part Two: Baseline, Months 1 & 2, Vaccination - 14, 21, 28, 120 days post-vaccination
  • 9. Tolerability of the treatment.; Timepoint(s): Part One: Baseline, Months 1,2,3,4,5,6,9,12
Publication(s)
Sorry, this information is not available
Result Reports
Sorry, this information is not available
Gender
Both
Age Range
Senior
Who Can Participate
Patient
Number of Participants
Planned Sample Size: 700; UK Sample Size: 700. Part One: 50 (200 screened); Part Two: 220 (500 screened)
Participant Inclusion Criteria
  • 1. Aged 65 years or above (30% 65-74 yrs old, 70% aged over 75 yrs)
  • 2. Cytomegalovirus (CMV) seropositive
  • 3. CMV-specific CD8+ and CD4+ T cell response over 0.5% of T cell pool at randomisation
  • 4. Human leuckocyte antigen (HLA) type of HLA-A1, A2, B7 or B8
  • 5. Predicted epidermal growth factor receptor (eGFR) > 50ml/min
  • 6. Liver function tests (LFT) in normal range.; Target Gender: Male & Female ; Lower Age Limit 65 years
Participant Exclusion Criteria
  • 1. On the following medication : Steroids, ciclosporin, mycophenolate, probenecid, tacrolimus, theophylline
  • 2. Significant chronic illness as assessed by clinical team
  • 3. History of cardiovascular event in the last 6 months
  • 4. General practitoner (GP) considers inappropriate to take part
  • 5. Unable to provide written consent
Trial Location(s)
Cancer Research UK Clinical Trials Unit - Birmingham
Birmingham
England
B15 2TT
Trial Contact(s)
Primary Trial Contact
Dr Odette Chagoury
o.l.chagoury@bham.ac.uk
Other Trial Contacts
Sorry, this information is not available
Countries Recruiting
United Kingdom
Scientific Title
A randomised controlled trial aimed at enhancing immunity to influenza in elderly individuals through reversal of immune senescence mediated by herpes virus infection
EudraCT Number
2011-000092-13
Funder(s)
  • Medical Research Council (MRC) (UK) (Grant Codes: 94820)
Other Study ID Numbers
10177
Sponsor(s)
University of Birmingham (UK)
Key Dates

Recruitment Start Date

01 Nov 2011

Recruitment End Date

01 Jan 2014

Trial Start Date

01 Nov 2011

Trial End Date

01 Jan 2014

Date Assigned

17 Aug 2011

Last Updated

27 Jun 2012